Researchers sought to estimate the incidence for shingles in adults with MS and in a general immunocompetent population.
Consortium Of Multiple Sclerosis Centers 2023 News
In an unblinded observational study, researchers assessed psychological, biological, and MRI changes associated with mindfulness-based stress reduction in MS.
Researchers assessed the feasibility of a 12-week high-intensity forced exercise or voluntary aerobic exercise intervention, and examined the impact on health-related quality of life and fatigue in patients with MS.
Researchers sought to examine the influence of S1P receptor modulators’ clinical management considerations on the preferences of patients with RRMS in the US.
Researchers sought to review pregnancy outcomes during ozanimod use in the clinical development program in all studies in which patients with RMS, UC, or CD or volunteer control individuals received ozanimod.
Researchers sought to fill in a gap regarding the psychosocial functioning of Hispanic and Black/African American individuals with multiple sclerosis in the US vs Latin America.
In an interim analysis, researchers reported on the open-label extension period on safety and tolerability of VidoCa in relapsing-remitting MS.
Researchers sought to report MRI, efficacy, and safety outcomes at week 96 of the phase 2b trial long-term safety extension in patients with relapsing MS and highly active disease.
Researchers sought to assess the relationship between obesity and diagnosis of myelin oligodendrocyte glycoprotein–associated disease and neuromyelitis optica in a diverse population.
Using optical coherence tomography angiography, researchers compared retinal microvasculature in patients with MS vs healthy individuals.
Researchers sought to describe the risk and outcomes for COVID-19 infection in patients with NMOSD who receive inebilizumab.
Researchers sought to examine the effects of fatigue on cognition in patients with MS via the MFIS and SDMT, before and during MEG study.
Researchers sought to compare real-world safety profiles of dimethyl fumarate and fingolimod via data from the FDA’s Adverse Event Reporting System database.
Researchers sought to compare the effects of a diet and therapeutic lifestyle telehealth intervention vs standard of care on perceived quality of life and fatigue in patients newly diagnosed with CIS or RRMS.
In a secondary data analysis, researchers estimated health resource utilization (HRU), including infection-related HRU, relapses, and costs in patients with stable MS who switched from anti-CD20 to fumarate.
Researchers reported on the primary safety and efficacy data from patients with early RRMS, treated with ocrelizumab over 4 years in the open-label, single-arm, phase 3b ENSEMBLE study.
Researchers sought to investigate the humoral response of patients with RMS, treated with evobrutinib who received mRNA and non-mRNA COVID-19 vaccines during the open-label extension of a phase II clinical trial.
In a retrospective, cross-sectional study, researchers characterized MS presentation in Latinx patients compared with non-White Latinx patients.